Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00113230|
Recruitment Status : Completed
First Posted : June 7, 2005
Results First Posted : November 13, 2009
Last Update Posted : August 7, 2012
|Condition or disease||Intervention/treatment||Phase|
|Rectal Cancer||Drug: Avastin (Bevacizumab, RHUMAB VEGF) Drug: Capecitabine Radiation: Radiation Therapy||Phase 2|
Avastin [RHUMAB VEGF, Bevacizumab] is a drug that has damaging effects on blood vessel growth in tumors.
Before treatment starts, you will have a complete physical exam. About 2 tablespoons of blood will be drawn for routine tests and a urine test will be performed. Chest x-rays and CT scans of the abdomen and pelvis will be done. Women who are able to have children must have a negative blood pregnancy test.
You will receive radiation therapy once a day for 5 days in a row (Monday-Friday) for 5 weeks and three days (a total of 28 treatments). You will take the chemotherapy drug capecitabine by mouth twice a day on each of the days that you receive radiation therapy. These pills will not be taken on Saturday and Sunday. You must not take cimetidine, and must be off of coumadin for at least one week and sorivudine and brivudine for at least four weeks before starting capecitabine and while taking capecitabine.
You will receive the drug Avastin by vein once every 2 weeks for six weeks (a total of three doses). The infusion will at first last 90 minutes. If there are no allergic reactions, fevers or chills, it will be shortened to 60 minutes and then 30 minutes for later infusions.
During the study, you will have physical exams, including weekly blood tests (about 2 teaspoons). The possible development of side effects will be closely monitored.
All participants will have surgical removal of the rectal tumor 6-8 weeks after the completion of treatment as they would for the standard of care for their disease. No patients will have surgery before 6 weeks.
After participation in this study is over, you will have follow-up evaluation as needed for standard of care.
THIS IS AN INVESTIGATIONAL STUDY. Capecitabine is approved by the FDA, but Avastin has not yet been evaluated for approval.
About 50 patients will take part in the study. All will be enrolled at the M. D. Anderson.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||25 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Trial Of Neoadjuvant Concurrent Capecitabine, RHUMAB VEGF (Avastin) And Radiotherapy In Patients Presenting With Locally Advanced Rectal Cancer|
|Study Start Date :||February 2005|
|Actual Primary Completion Date :||January 2009|
|Actual Study Completion Date :||January 2009|
Capecitabine, Avastin (RHUMAB VEGF/Bevacizumab) And Radiotherapy
Drug: Avastin (Bevacizumab, RHUMAB VEGF)
Starting Dose 5 mg/kg intravenously on day one of radiotherapy, given every 2 weeks +/- 2 days for a total of 3 doses.
900 mg/m^2 by mouth twice a day during days of radiation for all five weeks of therapy.
Other Name: Xeloda
Radiation: Radiation Therapy
45 Gy in 25 fractions to the pelvis followed by 5.4 Gy as a boost dose to the primary tumor with margin, for a total dose of 50.4 Gy over 28 treatment days.
- Pathologic Local Tumor Response [ Time Frame: Baseline to approximately 5 Months (Following 28 days of treatment, chemotherapy and surgical resection of tumor) ]At follow-up evaluation after completion of neoadjuvant and surgical therapy, resected primary tumor classified based on routine pathology staining in the following manner: Pathologic Complete Response (no evidence of residual cancer); Microscopic Residual (no grossly detected disease, but evidence of microscopic residual disease); and Gross Residual Disease.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00113230
|United States, Texas|
|UT M. D. Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Christopher H. Crane, MD||M.D. Anderson Cancer Center|